Necessity of Anti-HBc and Anti-HBs Screening in Korean Blood Donation Program: Study using LG Anti-HBc and LG Anti-HBs ELISA Kit and HBV Nucleic Acid Amplification Test.
- Author:
Heung Sup SUNG
1
;
Heung Bum OH
;
Byoung Kap HWANG
;
Mi Jin SOHN
Author Information
1. Department of Clinical Pathology, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
HBV;
Anti-HBc;
Blood Donor;
LG Anti-HBc ELISA;
LG Anti-HBs ELISA;
Nucleic acid amplification test
- MeSH:
Blood Donors*;
DNA;
Enzyme-Linked Immunosorbent Assay*;
Hepatitis B;
Hepatitis B Surface Antigens;
Humans;
Korea;
Mass Screening*;
Nucleic Acid Amplification Techniques*;
Polymerase Chain Reaction;
Seoul;
Tissue Donors
- From:Korean Journal of Blood Transfusion
2001;12(1):1-10
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Post-transfusion hepatitis B remains a risk for recipients of HBsAg negative bloods in Korea. The usefulness of anti-HBc screening for blood donors to reduce the risk of HBV transmission was evaluated in this study using LG Anti-HBc and LG Anti-HBs ELISA (LG Chemicals, Seoul, Korea) and HBV nucleic acid amplification test. METHOD: Sera from 2,274 HBsAg-negative blood donors were tested of anti-HBc and anti-HBs by LG Anti-HBc and LG Anti-HBs ELISA, respectively. Using 260 samples from HBsAg-negative blood donors and 62 FANA-positive samples, reactivity to LG Anti-HBc ELISA were compared with COBAS CORE Anti-HBc EIA (Roche Diagnostics, Basel, Switzerland). The precision of LG Anti-HBc was also tested. The nucleic acid amplification of 97 primary pools prepared from 2,274 samples was carried out, and then HBV presence was confirmed in individual samples. RESULT: Of 2,274 HBsAg-negative blood donors, 531 (23.4%) were positive for anti-HBc and 32 (1.4%) were anti-HBc positive/ anti-HBs negative. The concordance rate of LG Anti-HBc ELISA and COBAS was 97.8% (315/322). The intra-run and inter-run coefficient of variation was 4.7-10.2% and 2.5-11.4%, respectively. Thirteen pools showed initial positive in HBV PCR, but seven pools (53.8%) were finally found to be false positive. Of six true positive pools, seven samples were confirmed to have HBV DNA. The HBV detection rate was 6.3% (2/32) among donors whose results were anti-HBc positive/ anti-HBs negative. CONCLUSION: Among screen-negative blood donors, 6.3% of donors whose seroreactivity was anti-HBc positive/ anti-HBs negative were positive for HBV by nucleic acid amplification test, while donors showing such seroreactivity were only 1.4%. It is suggested that an introduction of anti-HBc and anti-HBs testing in Korean Blood Donation program be efficient to attain safety from HBV transmission.
